Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.

[1]  廣井 正彦.  生殖おもしろ話(70)選択的エストロゲン受容体修飾物質(selective estrogen-receptor modulators; SERMs) , 2006 .

[2]  M. Ellis,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.

[3]  A. Buzdar.  The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months , 2003, Breast Cancer Research and Treatment.

[4]  R. Yates,et al.  A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers , 2002, British Journal of Cancer.

[5]  B. Sherwin,et al.  Estrogen and cognitive aging in women. , 2002, Trends in pharmacological sciences.

[6]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[9]  D. Bentrem,et al.  Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  V. Cavaillès.  Estrogens and receptors: an evolving concept. , 2002, Climacteric : the journal of the International Menopause Society.

[11]  P. Lønning,et al.  Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer , 2002, Breast Cancer Research and Treatment.

[12]  Y. Yamamoto.  A novel antiestrogen, TAS-108 (SR16234) shows full antagonistic activity to ER alpha and beta with a unique mechanism , 2002 .

[13]  M. Cotreau,et al.  Multiple‐Dose, Safety, Pharmacokinetics, and Pharmacodynamics of a New Selective Estrogen Receptor Modulator, ERA‐923, in Healthy Postmenopausal Women , 2002, Journal of clinical pharmacology.

[14]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Lønning,et al.  High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy , 2001, Breast Cancer Research and Treatment.

[16]  C. Hudis,et al.  Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  V. Jordan,et al.  Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Jubelirer,et al.  The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia. , 2000, The West Virginia medical journal.

[20]  V. Kataja,et al.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Howell,et al.  ICI 182,780 (Faslodex™) , 2000, Cancer.

[22]  D. Hayes,et al.  Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer , 1999, Breast Cancer Research and Treatment.

[23]  L. Hartmann,et al.  Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis , 1999, Breast Cancer Research and Treatment.

[24]  S. Hoffman,et al.  Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. , 1998, Endocrinology.

[25]  C. Turner,et al.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[26]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[27]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[28]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[29]  P. Hietanen,et al.  Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.

[30]  S. Johnston.  Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications. , 1997, Anti-cancer drugs.

[31]  L. Kangas,et al.  A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer , 1997, Breast Cancer Research and Treatment.

[32]  L. Wiseman,et al.  Toremifene , 1997, Drugs.

[33]  A. Howell,et al.  Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. , 1996, British Journal of Cancer.

[34]  A. Kauppila,et al.  Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. , 1995, Gynecologic oncology.

[35]  Y. Ma,et al.  Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. , 1995, Bone.

[36]  D. Hayes,et al.  Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Dowsett,et al.  Idoxifene: report of a phase I study in patients with metastatic breast cancer. , 1995, Cancer research.

[38]  B. Rattel,et al.  Preclinical data for Droloxifene. , 1994, Cancer letters.

[39]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[40]  M. Green,et al.  Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  O. Abe,et al.  [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen]. , 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

[42]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[43]  S. Robinson,et al.  Preclinical studies with toremifene as an antitumor agent , 1990, Breast Cancer Research and Treatment.

[44]  G. Bertelli,et al.  Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels , 1988, Breast Cancer Research and Treatment.

[45]  U. Eppenberger,et al.  In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. , 1985, European journal of cancer & clinical oncology.

[46]  J. Lokich,et al.  Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer , 1985, American journal of clinical oncology.

[47]  L. Beex,et al.  Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. , 1981, Cancer treatment reports.

[48]  M. Lippman,et al.  Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. , 1977, Cancer research.

[49]  E. Engelsman,et al.  Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. , 1975, British medical journal.

[50]  J. Dodge,et al.  Selective estrogen receptor modulators (SERMs). , 1970, Current pharmaceutical design.

[51]  E. Brandstrup,et al.  Foetal and neonatal mortality. , 1947, Lancet.

[52]  A. Haddow,et al.  Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.

[53]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[54]  P. Dombernowsky,et al.  Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial , 2004, Breast Cancer Research and Treatment.

[55]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[56]  A. Milla-Santos,et al.  Phase III Randomized Trial of Toremifene vs Tamoxifen in Hormonodependant Advanced Breast Cancer , 2004, Breast Cancer Research and Treatment.

[57]  S. Pyrhönen,et al.  High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment , 2004, Breast Cancer Research and Treatment.

[58]  G. Hortobagyi,et al.  Neoplasms of the Breast , 2003 .

[59]  S. Lundgren,et al.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. , 1997, British Journal of Cancer.

[60]  M. Dowsett,et al.  The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. , 1997, British Journal of Cancer.

[61]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[63]  S. Gundersen,et al.  Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer. , 1992, Acta oncologica.

[64]  G. Hortobagyi,et al.  Phase II evaluation of Ly156758 in metastatic breast cancer. , 1988, Oncology.

[65]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.

[66]  A. Forrest,et al.  The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. , 1980, European journal of cancer.